Opinion

Sara Imarisio, Head of Strategic Initiatives at Alzheimer’s Research UK, reveals what dementia research could deliver and how Alzheimer’s research can help us re-imagine a future in which lives are saved.  Alzheimer’s and other forms of dementia have been impacted by Covid-19. With many labs forced to close during lockdown, and social distancing measures limiting the time […]

Chun-wa Chung discusses why the world of drug discovery excites her and offers advice for early career professionals, emphasising her admiration for how the industry has managed to re-imagine its potential and anticipating the opportunity to re-connect and share these learnings.  Career journey  Chung’s career within drug discovery and with GlaxoSmithKline (GSK) spans over 20 years. She is […]

Valo Health is a technology company built to transform drug discovery and development using human-centric data and artificial intelligence-powered compute. VP of Integrated Research, Guido Lanza talks to DDW in its Drug Discovery 2021 supplement about how Valo Health is re-inventing and innovating to overcome the fragmented, outdated drug discovery and development process that exists today.  According […]

The Fall Issue of the Drug Discovery World Magazine is accompanied by an exclusive DDW & ELRIG UK supplement ahead of ELRIG UK’s Drug Discovery 2021 in Liverpool, October 19-20, 2021. In it, ELRIG UK’s General Manager Sanj Kumar welcomes the event and introduces the themes.   In 2019, ELRIG’s flagship scientific conference, Drug Discovery, attracted over […]

The Fall Issue of the Drug Discovery World Magazine is accompanied by an exclusive DDW & ELRIG UK supplement ahead of ELRIG UK’s Drug Discovery 2021 in Liverpool, October 19-20, 2021. DDW Editor Lu Rahman welcomes the event and introduces the themes.   To say that I – as well as the entire DDW team – am excited […]

In 18 months, vaccine research advanced AI in medicine by five to seven years. That’s cause for optimism — and investment — in the digital transformation of clinical development. Jeff Elton, CEO of ConcertAI, who has extensive experience in this sector, shares his insight with DDW. There has been a recent flurry of news at […]

DDW’s Editor Lu Rahman comments and gives perspective on the global drug discovery and development market in the UK. As I’m writing this in the UK, there are reports of gas supply shortages, a lack of CO2­ affecting food supply, the price of energy is rising and the cherry on top – murmurings of cancelling […]

By Rafael Rosengarten, CEO of Genialis and Executive Member of the Board of Directors for the Alliance for Artificial Intelligence in Healthcare (AAIH)  How does a late-stage clinical trial fail when the preceding trials showed such promise? The likely reason is that the patients in the earlier trials were not representative of the larger population.    […]

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks with Dr Orloff about his career and the future of […]